Currently, key targets for CAR-T-cell therapy in MS include the following antigens: CD19 (B cells), BCMA (plasma cells, plasmablasts), CD38 (plasma cells, early B cells), and MOG/MBP (for CAAR-T cells). Here, TNFRSF17 is linked to myeloid sarcoma.